What caused the large gain in 2003 operating profit?

The company recorded a $17.3 million net gain from the final settlement of its insurance claim for the January 29, 2003 explosion and fire at its Kinston, North Carolina plant. The $66.0 million maximum recovery was reflected as a gain after $48.7 million of related costs and expenses, including business interruption costs, insured incremental costs, property book value and uninsured legal costs.

How is the Kinston plant recovery expected to affect 2004?

The filing states that higher production costs of approximately $10 million to $12 million are expected to continue until about September 2004, which will lower the gross margin of the Pharmaceutical Systems segment. Full production capacity is expected to return to historical levels by September 2004, and no further business interruption reimbursements will be received.

How concentrated is the customer base?

Becton Dickinson and Company accounted for approximately 12% of 2003 consolidated net sales. The next ten largest customers, excluding BD, accounted for approximately 31% of net sales, and none of them exceeded 4% individually.

What is the company's near-term debt and refinancing situation?

Debt includes $100.0 million of senior notes at a fixed 6.81% rate due 2009 and $67.0 million drawn under a revolving credit facility due in July 2005. The company anticipates refinancing its existing facilities in the second quarter of 2004 and states that its financial condition should be sufficient to meet cash requirements at least through July 2005.

What is the status of the Drug Delivery Systems segment?

The segment, which develops ChiSys nasal and TARGIT oral delivery technologies, recorded an operating loss of $17.5 million in 2003. The company's strategy is to advance products through early-phase clinical trials and out-license them for milestone fees, development reimbursements and royalties, and it expects a licensing agreement for a generic nasal allergy product in the first half of 2004.

WST 10-K FY2003 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K filed March 12, 2004. Cited figures are marked; the original filing is the authoritative source.

West Pharmaceutical Services, Inc. reported consolidated net sales of $490.7 million^a for 2003, up from $419.7 million in 2002 and $392.3 million in 2001, and net income of $31.9 million, or $2.19 per diluted share, compared with $18.4 million in 2002.

Operating profit rose to $54.5 million^b from $26.7 million, helped by a $17.3 million net gain from the final settlement of the insurance claim for the January 2003 explosion and fire at the Kinston, North Carolina plant, which resulted in six deaths. Results also absorbed a $7.0 million charge tied to the U.K. device plant. Pharmaceutical Systems, the core closures and components business, generated $483.4 million of net sales and $88.2 million of operating profit, while Drug Delivery Systems posted an operating loss of $17.5 million.

The company's balance sheet strengthened over the year. Total assets grew to $623.6 million and shareholders' equity rose to $257.6 million^c, while total debt was $175.0 million, equal to 40.5% of total invested capital, a 6.0 percentage point improvement from year-end 2002. Cash flow from operations was $69.2 million, against capital spending of $60.8 million, including $14.1 million for the Kinston rebuild.

The filing states that full production capacity at Kinston is expected to return to historical levels by September 2004, and that higher production costs of approximately $10 million to $12 million^d are expected in 2004. Key risks flagged in the filing include a $100.0 million senior notes obligation and a revolving credit facility maturing in July 2005, with refinancing anticipated in the second quarter of 2004. Becton Dickinson accounted for approximately 12% of 2003 consolidated net sales, and sales outside the United States were approximately 50%.

A wrongful-death-type lawsuit tied to the Kinston explosion remains pending in state court, and the company states it believes its insurance is sufficient to cover expected litigation losses. The Drug Delivery Systems segment, which develops nasal and oral delivery technologies, remains loss-making, with management prioritizing near-term licensing opportunities.

02—Key points

Key Highlights

Net sales rose to $490.7 million in 2003 from $419.7 million in 2002, with the filing noting about 7% of the increase came from currency strength against the U.S. dollar.
Net income was $31.9 million, or $2.19 per diluted share, versus $18.4 million in 2002, which included discontinued operations.
The Kinston, N.C. insurance settlement of $66.0 million produced a net gain of $17.3 million, which the company reports within operating results.
Pharmaceutical Systems operating profit was $88.2 million, while Drug Delivery Systems posted an operating loss of $17.5 million.
Total debt was $175.0 million at year-end, representing 40.5% of total invested capital; shareholders' equity rose to $257.6 million.
Cash flow from operations was $69.2 million, against capital spending of $60.8 million; the company expects 2004 capital spending of approximately $57.0 million.
The pharmaceutical systems order backlog was $131.6 million at December 31, 2003, up from $118.8 million a year earlier.

03—Questions

Frequently Asked Questions

What caused the large gain in 2003 operating profit?
The company recorded a $17.3 million net gain from the final settlement of its insurance claim for the January 29, 2003 explosion and fire at its Kinston, North Carolina plant. The $66.0 million maximum recovery was reflected as a gain after $48.7 million of related costs and expenses, including business interruption costs, insured incremental costs, property book value and uninsured legal costs.
How is the Kinston plant recovery expected to affect 2004?
The filing states that higher production costs of approximately $10 million to $12 million are expected to continue until about September 2004, which will lower the gross margin of the Pharmaceutical Systems segment. Full production capacity is expected to return to historical levels by September 2004, and no further business interruption reimbursements will be received.
How concentrated is the customer base?
Becton Dickinson and Company accounted for approximately 12% of 2003 consolidated net sales. The next ten largest customers, excluding BD, accounted for approximately 31% of net sales, and none of them exceeded 4% individually.
What is the company's near-term debt and refinancing situation?
Debt includes $100.0 million of senior notes at a fixed 6.81% rate due 2009 and $67.0 million drawn under a revolving credit facility due in July 2005. The company anticipates refinancing its existing facilities in the second quarter of 2004 and states that its financial condition should be sufficient to meet cash requirements at least through July 2005.
What is the status of the Drug Delivery Systems segment?
The segment, which develops ChiSys nasal and TARGIT oral delivery technologies, recorded an operating loss of $17.5 million in 2003. The company's strategy is to advance products through early-phase clinical trials and out-license them for milestone fees, development reimbursements and royalties, and it expects a licensing agreement for a generic nasal allergy product in the first half of 2004.

04—Continue

← View all 10-K filings